

**Pipeline**

**355** Candidate drug submissions received via open submission system

**228** unique suggestions

**OVER 107** unbiased evidence based briefs created

**Process**

**33** recommendations to trial

**16** UK-CTAP meetings  
**47** Independent subgroup meetings

**7** Independent expert subgroups covering key areas of disease

**Clinical Trials**

Recommended drugs to national publicly funded platform trials **7**

Integrated trial coverage from phase 1-3 in diverse clinical settings

**OVER 50,000** patients recruited to trial across the UK

**Equality, Diversity & Inclusion**

Connected with over **200** collaborators across academia, industry and regulatory authorities

**47** world leading scientific experts from **25+** flagship institutions

**Diverse & inclusive programme** with panel members from diverse ethnicities, genders & geographies



Evidence-based high-quality scientific due diligence by regulatory and research specialists, experienced clinicians and Pharmacokinetics & Pharmacodynamic (PK/PD) specialists.



Prophylaxis, community (incl. care homes) and hospital (incl. ICU) clinical trial settings. Immunocompromised and long COVID patients also recruited.

Find out more: Outcomes of the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP) – UKRI